S

Sanofi

Global pharma company; vaccines and R&D

T1D Medical Advisor

Full-TimeUpdated on 10/15/2026Deadline 11/29/26
No salary listed
Mid
PharmD, PhD, MD
Tokyo, Japan
In Person
Biology & Biotech

About the job

Requirements
  • Background in medical affairs, research and development, or clinical research within the pharmaceutical industry, including experience in a Medical Science Liaison or Medical Advisor/Medical Manager capacity.
  • Strong scientific acumen in immunology, endocrinology, or a related therapeutic area.
  • Ability to critically analyze and interpret clinical and real-world data.
  • Experience in medical writing and publication activities.
  • Strategic thinking and ability to operate independently while collaborating across functions.
  • Strong interpersonal skills and commitment to serving healthcare professional needs.
  • Ability to communicate clearly and adapt to changing situations.
  • Advanced degree (MD, PhD, PharmD, or equivalent) in a relevant medical or scientific discipline, or an equivalent combination of education and experience.
  • Fluency in Japanese.
  • Business-level English reading and writing proficiency.
Responsibilities
  • Support development and execution of the Japan Medical Plan for Type 1 Diabetes, provide scientific input for medical content, and contribute to cross-functional initiatives including regulatory interactions and lifecycle planning.
  • Lead and support medical communication activities, including publication planning, congress and symposia participation, and advisory board presentations, to advance scientific exchange with the medical community.
  • Build and nurture relationships with key opinion leaders and scientific societies, collect and share medical insights to inform strategy and strengthen Sanofi's presence in the Type 1 Diabetes space.
  • Plan and execute company-sponsored clinical studies and externally sponsored research collaborations, including post-approval studies and Investigator-Sponsored Studies, to generate real-world evidence.
  • Analyze real-world data with internal and external experts to deepen understanding of Type 1 Diabetes and support evidence-based decision-making.
  • Partner with Medical Science Liaisons and global medical teams to develop field strategies addressing the evolving needs of healthcare professionals and patients.
  • Ensure medical activities comply with scientific integrity standards, applicable regulations, and guidelines.
Desired Qualifications
  • Prior involvement in clinical trial or study management is a strong advantage.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)